Literature DB >> 16308415

Urotensin II is raised in children with congenital heart disease.

C M Simpson, D J Penny, C F Stocker, L S Shekerdemian.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16308415      PMCID： PMC1860725          DOI： 10.1136/hrt.2005.074039

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  9 in total

1.  Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat.

Authors:  M R MacLean; D Alexander; A Stirrat; M Gallagher; S A Douglas; E H Ohlstein; I Morecroft; K Polland
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

2.  Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14.

Authors:  R S Ames; H M Sarau; J K Chambers; R N Willette; N V Aiyar; A M Romanic; C S Louden; J J Foley; C F Sauermelch; R W Coatney; Z Ao; J Disa; S D Holmes; J M Stadel; J D Martin; W S Liu; G I Glover; S Wilson; D E McNulty; C E Ellis; N A Elshourbagy; U Shabon; J J Trill; D W Hay; E H Ohlstein; D J Bergsma; S A Douglas
Journal:  Nature       Date:  1999-09-16       Impact factor: 49.962

3.  Plasma urotensin II in heart failure.

Authors:  A Mark Richards; M Gary Nicholls; John G Lainchbury; Stephen Fisher; Timothy G Yandle
Journal:  Lancet       Date:  2002-08-17       Impact factor: 79.321

4.  Activation of pulmonary mitogen-activated protein kinases during cardiopulmonary bypass.

Authors:  Tanveer A Khan; Cesario Bianchi; Eugenio G Araujo; Marc Ruel; Pierre Voisine; Frank W Sellke
Journal:  J Surg Res       Date:  2003-11       Impact factor: 2.192

5.  Congestive heart failure and expression of myocardial urotensin II.

Authors:  Stephen A Douglas; Lara Tayara; Eliot H Ohlstein; Nadine Halawa; Adel Giaid
Journal:  Lancet       Date:  2002-06-08       Impact factor: 79.321

6.  Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases.

Authors:  Döne Onan; Luisa Pipolo; Eunice Yang; Ross D Hannan; Walter G Thomas
Journal:  Mol Endocrinol       Date:  2004-06-17

7.  Plasma concentration of urotensin II is raised in hypertension.

Authors:  Bernard M Y Cheung; Raymond Leung; Yu Bun Man; Louisa Y F Wong
Journal:  J Hypertens       Date:  2004-07       Impact factor: 4.844

Review 8.  The effect of modified ultrafiltration on the postoperative course in patients with congenital heart disease.

Authors:  J William Gaynor
Journal:  Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu       Date:  2003

9.  Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators.

Authors:  Douglas G Johns; Zhaohui Ao; Diane Naselsky; Christopher L Herold; Kristeen Maniscalco; Lea Sarov-Blat; Klaudia Steplewski; Nambi Aiyar; Stephen A Douglas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-09-30       Impact factor: 3.000
  9 in total
  7 in total

Review 1.  Urotensin-II and cardiovascular diseases.

Authors:  Nicolas Bousette; Adel Giaid
Journal:  Curr Hypertens Rep       Date:  2006-12       Impact factor: 5.369

2.  DNA Methylation Analysis of Turner Syndrome BAV.

Authors:  Jacob Gutierrez; Brett A Davis; Kimberly A Nevonen; Samantha Ward; Lucia Carbone; Cheryl L Maslen
Journal:  Front Genet       Date:  2022-05-31       Impact factor: 4.772

Review 3.  Role of urotensin II and its receptor in health and disease.

Authors:  John McDonald; Madura Batuwangala; David G Lambert
Journal:  J Anesth       Date:  2007-08-01       Impact factor: 2.078

4.  Potential Clinical Implications of the Urotensin II Receptor Antagonists.

Authors:  Philip Tsoukas; Emilie Kane; Adel Giaid
Journal:  Front Pharmacol       Date:  2011-07-22       Impact factor: 5.810

5.  NOX4 mediates activation of FoxO3a and matrix metalloproteinase-2 expression by urotensin-II.

Authors:  Isabel Diebold; Andreas Petry; Maximilian Burger; John Hess; Agnes Görlach
Journal:  Mol Biol Cell       Date:  2011-09-30       Impact factor: 4.138

6.  Plasma Urotensin II levels in children and adolescents with chronic kidney disease: a single-centre study.

Authors:  Anastasia Garoufi; Styliani Drapanioti; Antonios Marmarinos; Varvara Askiti; Andromachi J Mitsioni; Maria Mila; Georgia Grigoriadou; Dimitrios Georgakopoulos; Constantinos J Stefanidis; Dimitrios Gourgiotis
Journal:  BMC Nephrol       Date:  2017-03-31       Impact factor: 2.388

7.  The Urotensin II System and Carotid Atherosclerosis: A Role in Vascular Calcification.

Authors:  Isabella Albanese; Stella S Daskalopoulou; Bin Yu; Zhipeng You; Jacques Genest; Alawi Alsheikh-Ali; Adel G Schwertani
Journal:  Front Pharmacol       Date:  2016-06-07       Impact factor: 5.810
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.